Champions Biotechnology, Inc. has announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts™ in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc.
"ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates," Burkett added.